Skip to content

Real-world analytical and diagnostic evaluation of the Abbott i-STAT Alinity point-of-care high-sensitivity troponin I assay in a UK emergency department.

Oct 2026 · Annals of Clinical Biochemistry · pp. 45632261499915 · 0 citations
Medicine

Abstract

Background

High-sensitivity cardiac troponin (hs-cTn) testing is central to emergency department assessment of suspected acute coronary syndrome. Point-of-care hs-cTn testing may reduce turnaround time, but local analytical and clinical evaluation is required before implementation.

Methods

In a single-centre real-world evaluation, paired whole-blood and plasma samples from patients with suspected acute coronary syndrome were analysed using the Abbott i-STAT Alinity point-of-care hs-cTnI assay and the Alinity laboratory hs-cTnI assay. Imprecision, method comparison, threshold concordance, diagnostic discrimination for adjudicated Type 1 myocardial infarction (MI), and potential effects of haemolysis, icterus, lipaemia and haematocrit were assessed.

Results

Low-level imprecision was below 10% CV. Concordance at the <5 ng/L rule-out threshold was high (84.1%); all discordant classifications reflected higher POCT values, with no false-negative rule-outs. Both assays showed similar discrimination for adjudicated Type 1 MI and 100% observed sensitivity and negative predictive value at the 5 ng/L threshold, although confidence intervals were wide. POCT specificity was lower than laboratory specificity. Method comparison showed a modest positive POCT bias, and regression analyses did not identify clinically meaningful effects of haemolysis, icterus, lipaemia or haematocrit.

Conclusion

The Abbott i-STAT Alinity POCT hs-cTnI assay demonstrated analytical performance and clinical concordance supportive of local implementation, with similar diagnostic discrimination to the Alinity laboratory hs-cTnI assay in a small cohort. Larger prospective studies are needed to confirm clinical safety and workflow impact.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.